Beijing-based BioGeometry raised more than $100 million in Series A funding for AI-driven protein design, positioning the company to scale drug discovery and development work. The funding adds to the push by Chinese startups to apply generative AI and protein-engineering pipelines to new therapeutic targets. BioGeometry, founded about four years ago, frames its platform around AI-supported protein design tasks that can be used downstream in R&D programs. For investors and pipeline strategists, the deal signals continued appetite for AI-first discovery infrastructure that can translate designs into experimentally testable molecules. The immediate industry implication is competitive pressure for protein-platform scale, assay integration, and model-to-biology workflow reliability—areas where large cash infusions can accelerate both compute and experimental throughput.